Efficacy and safety of silymarin containing antioxidant serum as an adjuvant treatment of mild-to-moderate acne vulgaris: A prospective, open-label pilot study

被引:9
|
作者
Kim, Jemin [1 ]
Lee, Yun Na [1 ]
Lee, Joohee [1 ]
Lee, Sang Gyu [1 ]
Kim, Hyun [2 ]
Choi, Ye Seul [2 ]
Draelos, Zoe Diana [3 ]
Kim, Jihee [1 ,2 ]
机构
[1] Yonsei Univ, Severance Hosp, Cutaneous Biol Res Inst, Dept Dermatol,Coll Med, Seoul, South Korea
[2] Yonsei Univ, Yongin Severance Hosp, Dept Dermatol, Coll Med, Seoul, South Korea
[3] Dermatol Consulting Serv, Durham, NC USA
关键词
acne; cosmeceutical; oral isotretinoin; silymarin; SALICYLIC-ACID; DERMOCOSMETICS;
D O I
10.1111/jocd.15439
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Silymarin is the active component of milk thistle, which has antioxidant properties by scavenging free radicals and potential comedolytic properties. Aims This study aimed to assess the efficacy and safety of 0.5% silymarin-loaded antioxidant serum (SAS) used to treat mild-to-moderate acne. Patients and Methods A prospective, open-label pilot study was conducted. We enrolled 22 Korean acne patients who applied the 0.5% SAS on the whole face twice daily while continuing the current anti-acne medications. Grade of acne severity, individual lesion counts, sebum output levels, skin erythema, and melanin pigmentation were assessed. Results After a 4-week application, the modified Global Acne Grading Score (mGAGS), Global Evaluation Acne (GEA) scale, and the acne lesion counts were significantly decreased. Sebum secretion, skin pigmentation, and erythema were also reduced during the study period, yet only the melanin pigmentation index reached statistical significance. Subgroup analysis revealed that the patients who took the low-dose oral isotretinoin during the study period showed more noticeable improvements in skin sebum output and melanin pigmentation. Additionally, no adverse event was associated with using the 0.5% SAS. Conclusion The 0.5% silymarin-containing antioxidant formulation improved acne's clinical severity and related skin biophysical parameters.
引用
收藏
页码:561 / 568
页数:8
相关论文
共 50 条
  • [1] Efficacy and safety of artemether emulsion for the treatment of mild-to-moderate acne vulgaris: a randomized pilot study
    Shen, Wen-tong
    Wu, Yun
    He, Hui-qiong
    Yu, Yue
    Qin, Hai-hong
    Fei, Jian-biao
    Wang, Guo-jiang
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2021, 32 (07) : 762 - 765
  • [2] Efficacy and safety of non-surgical short-wave radiofrequency treatment of mild-to-moderate erythematotelangiectatic rosacea: a prospective, open-label pilot study
    Ben Wang
    Hong-fu Xie
    Yu-xuan Deng
    Ji Li
    Dan Jian
    Archives of Dermatological Research, 2022, 314 : 341 - 347
  • [3] Efficacy and safety of non-surgical short-wave radiofrequency treatment of mild-to-moderate erythematotelangiectatic rosacea: a prospective, open-label pilot study
    Wang, Ben
    Xie, Hong-fu
    Deng, Yu-xuan
    Li, Ji
    Jian, Dan
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2022, 314 (04) : 341 - 347
  • [4] Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study
    Kerdel, Franz R.
    Azevedo, Fabio A.
    Kerdel, Christina
    Don, Frank A.
    Fabbrocini, Gabriella
    Kerdel, Francisco A.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (02) : 170 - 176
  • [5] Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients
    Goh, M. S. Y.
    McCormack, C.
    Dinh, H. V.
    Welsh, B.
    Foley, P.
    Prince, H. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2007, 156 (05) : 990 - 996
  • [6] Efficacy and safety of rifaximin in the treatment of mild-moderate Crohn's disease: Results of an open-label pilot study
    Kornbluth, A
    Hunt, M
    George, J
    Latzman, G
    Rochester, J
    Fried-Boxt, E
    Legnani, P
    GASTROENTEROLOGY, 2005, 128 (04) : A579 - A579
  • [7] Prospective, Randomized, Open-Label Trial Comparing the Safety, Efficacy, and Tolerability of an Acne Treatment Regimen with and without a Probiotic Supplement and Minocycline in Subjects with Mild to Moderate Acne
    Jung, Gordon W.
    Tse, Jennifer E.
    Guiha, Isabella
    Rao, Jaggi
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2013, 17 (02) : 114 - 122
  • [8] A prospective, randomized, open-label trial comparing the safety, efficacy, and tolerability of an acne treatment regimen with and without a probiotic supplement and minocycline in subjects with mild to moderate acne
    Jung, Gordon
    Guiha, Isabella
    Rao, Jaggi
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB9 - AB9
  • [9] Efficacy and safety of Oral Azithromycin in the Treatment of Mild to Moderate Acne Vulgaris
    Ahmad, Shama
    Aman, Shahbaz
    Nadeem, Muhammad
    Kazmi, Atif Hasnain
    ANNALS OF KING EDWARD MEDICAL UNIVERSITY LAHORE PAKISTAN, 2011, 17 (04): : 442 - +
  • [10] An open-label, noncomparative, multicenter study of ramipril in the treatment of patients with mild-to-moderate hypertension
    Sadick, A
    Yusuf, MZ
    Reuter, M
    CLINICAL THERAPEUTICS, 1996, 18 (06) : 1161 - 1168